Organisational changes critical to EMA's sustainability, says new report
This article was originally published in SRA
Executive Summary
While the European Medicines Agency has proven effective in protecting human and animal health in the European region, the whole medicines authorisation system "is progressively attaining its maximum capacity", says a new report published by the European Commission1,2. Thus, there is an urgent need for the agency to appropriately alter its organisation to ensure its sustainability in the face of novel challenges.
You may also be interested in...
New European Commission Study To Review Experience With Human Drug Authorization Procedures
The European Commission is deciding on the terms of reference of an external study, to be completed in 2018, in order to comply with its legal obligation of publishing a general report every 10 years on the experience acquired with various EU marketing authorization procedures for human drugs.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.